Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merck KGaAXSWX:MER 84 Equity-to-Asset is 0.56 as of Mar. 2026, which is 22% above its 10-year median of 0.46. GuruFocus rates XSWX:MER with a GF Score™ of 84/100 and a GF Value™ of CHF129.05. The stock has 10 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Merck KGaA ranks worse than 57.1% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Merck KGaA's Total Stockholders Equity for the quarter that ended in Mar. 2026 was CHF27,070 Mil. Merck KGaA's Total Assets for the quarter that ended in Mar. 2026 was CHF48,303 Mil.
Therefore, Merck KGaA's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.56.
The historical rank and industry rank for Merck KGaA's Equity-to-Asset or its related term are showing as below:
XSWX:MER'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.46 Max: 0.6
Current: 0.56
During the past 13 years, the highest Equity to Asset Ratio of Merck KGaA was 0.60. The lowest was 0.35. And the median was 0.46.
XSWX:MER's Equity-to-Asset is ranked worse than 57.1% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:MER: 0.56
Merck KGaA (XSWX:MER) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Merck KGaA Equity-to-Asset Related Terms
Merck KGaA Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Merck KGaA's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MER vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck KGaA Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Merck KGaA's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Merck KGaA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck KGaA (XSWX:MER) has a Equity-to-Asset of 0.56 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Merck KGaA and its competitors. This is 22% above median its historical median of 0.46. Over the past decade, Merck KGaA's Equity-to-Asset has ranged from 0.35 to 0.60. According to the industry distribution chart, Merck KGaA ranks #575 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 57.1%.
Is Merck KGaA's Equity-to-Asset too high?
Merck KGaA's current Equity-to-Asset of 0.56 is 22% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.60. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Merck KGaA's value of 0.56 is 8.2% below this industry median. Based on the distribution chart, Merck KGaA ranks #575 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Merck KGaA has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Merck KGaA ranks #575 out of 1007 companies for Equity-to-Asset. This places Merck KGaA in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Merck KGaA's value of 0.56 is 8.2% below this benchmark. Historically, Merck KGaA's own Equity-to-Asset has ranged from 0.35 to 0.60 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.61, Merck KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck KGaA's current Equity-to-Asset of 0.56 is 8.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Merck KGaA and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck KGaA's current Equity-to-Asset is 0.56, which is 22% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Equity-to-Asset of 0.56. The stock's GF Value™ is CHF129.05, compared to a current price of CHF127.50 — trading 1.2% below its estimated fair value. The current Equity-to-Asset is 0.56, which is 22% above median its 10-year median of 0.46 and 8.2% below the Drug Manufacturers industry median of 0.61. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Equity-to-Asset is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck KGaA (XSWX:MER) Overvalued in 2026?
Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued.
The current stock price of CHF127.50 is trading 1.2% below its estimated GF Value™ of CHF129.05.
Key valuation signals for XSWX:MER:
Equity-to-Asset: 0.56 (22% above median its 10-year median of 0.46)
GF Value™: CHF129.05 vs. price of CHF127.50 (1.2% below fair value)
Industry Position: 8.2% below the Drug Manufacturers median (#575 of 1007)
No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score
Get the complete analysis for XSWX:MER
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MER has been successfully added to your 
